| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $18.2M | +40.5% |
| SG&A Expense | $9.4M | +36.0% |
| Operating Income | -$27.6M | -38.9% |
| Net Income | -$26.4M | -39.2% |
| EPS (Basic) | -$1.32 | -18.9% |
| EPS (Diluted) | -$1.32 | -18.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $31.6M | +70.7% |
| Current Assets | $31.7M | +70.4% |
| Total Assets | $31.7M | +70.4% |
| Current Liabilities | $13.3M | +49.5% |
| Total Liabilities | $13.3M | +49.5% |
| Stockholders' Equity | $18.4M | +89.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$16.0M | -30.7% |
| Financing Cash Flow | $29.1M | +149.8% |